Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,671

Document Document Title
WO/2022/162693A1
The present invention relates to a class of benzodiazepine compounds and a process for preparation thereof. The 1,5-benzodiazepine compounds effectively 5 function on targeted enzymes such as tyrosine kinase and dihydrofolate reductase (...  
WO/2022/133551A1
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...  
WO/2015/136557A9
The present invention provides compounds of formula (I), compositions, uses thereof and methods for inhibiting proliferation or obliterating cancer stem cells which includes killing; and/or inducing apoptosis in cancer stem cells. Includ...  
WO/2022/105542A1
Disclosed are a deuterated 1,4-benzodiazepine-2,5-dione compound and the use thereof. Provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. The disclosed 1,4-benzodiazepine-2,5-dione active com...  
WO/2022/099011A1
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is...  
WO/2022/082305A1
The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the am...  
WO/2022/086892A1
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.  
WO/2022/034616A1
Described herein is a method for treating and/or preventing a disease or disorder or condition associated with NETosis, the method comprising: administering to a subject a compound as disclosed herein, or its polymorph, stereoisomer, pro...  
WO/2022/022846A1
The present invention relates to a compound of general formula (I) wherein R1-7, Hy, and X are as defined in claim 1. Such compound of formula (I) binds to VDAC1 and is suitable for use in a method for treating diabetes or pre- diabetes ...  
WO/2022/000443A1
Provided herein are compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.  
WO/2021/249463A1
The present invention relates to a compound as represented by formula (I). Also provided are a composition and a preparation containing the compound, and a method for using and preparing the compound.  
WO/2021/237111A1
Disclosed herein, inter alia, are compounds for inhibiting Notch and uses thereof.  
WO/2021/237112A1
Disclosed herein, inter alia, are compounds for inhibiting Notch and uses thereof.  
WO/2021/226629A1
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses o...  
WO/2021/218863A1
The present invention relates to the field of chemical medicine, and in particular, to a 1,5-dihydro-2,4-benzodiazepine-3-one derivative and an application thereof. The 1,5-dihydro-2,4-benzodiazepine-3-one derivative provided by the pres...  
WO/2021/208945A1
Disclosed are a benzonitric heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a benzonitric heterocyclic compound represented by formula I, or a pharmaceutically acceptable sal...  
WO/2021/208918A1
Provided are a class of compounds, represented by formula (I"'), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds ...  
WO/2021/188620A1
Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sa...  
WO/2021/169963A1
Provided are a compound containing an aromatic group as well as a stereoisomer, a tautomer or a pharmaceutically acceptable salt of the compound. Further provided is a method related to preparation and use of the compound. A pharmaceutic...  
WO/2021/170913A1
Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic o...  
WO/2021/163676A1
The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I) wherein: R1 each is independently F, Cl, Br, I, OCH3, CN or NO2; R2 each is independently ...  
WO/2021/141969A1
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve t...  
WO/2021/018298A1
Disclosed is a class of indolo-seven-membered acyloxime compounds, and specifically disclosed are compounds as shown in formula (I), and pharmaceutically acceptable salts thereof.  
WO/2020/245213A1
The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising ...  
WO/2020/242923A1
This disclosure relates to uses of radiation and benzodiazepines optionally in combination with other anticancer agents for treating cancer. In certain embodiments, this disclosure relates to methods of using radiation, benzodiazepines, ...  
WO/2020/210662A1
The present disclosure provides compounds of formula (I), as described herein, their pharmaceutically acceptable salts, and their pharmaceutical compositions, which are effective in reducing the expression level of KLF5 or EGR1 in a livi...  
WO/2020/200283A1
In an embodiment of the present invention, a fluorenone ligand compound for an α7 nicotinic acetylcholine receptor represented by the following formula (I) is provided, wherein, X is a 6- to 10-membered nitrogen-containing heterocyclic ...  
WO/2020/192637A1
Disclosed are a solid form and a crystal form of a compound represented by formula (1) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related disease...  
WO/2020/184670A1
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...  
WO/2020/131000A1
The invention relates to a crystalline form of the Compound (I), wherein the crystalline form displays its strongest reflection, stated as a 2Θ value, at 25±0.2°, in an X-ray powder diffraction pattern. The invention also relates to a...  
WO/2020/127390A1
A method is provided for preparing a compound d having the formula (D) The method comprises carrying out the following reaction (c) → (d), where the reaction is carried out at a temperature of at least 100 °C and in the presence of a ...  
WO/2020/127385A1
A method is provided for preparing a compound d having the formula: Formula (I). The method comprises carrying out the following reaction: Formula (i), (ii), (d) where: step (i) is carried out in the presence of a metal catalyst and a hy...  
WO/2020/039631A1
Disclosed is a compound represented by formula (1): Q-CHR2 (1) (in the formula, Q represents a nitrogen-containing aliphatic group that includes two or more tertiary nitrogen atoms, and does not include oxygen, and R represents an alipha...  
WO/2020/035464A1
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...  
WO/2020/027304A1
Provided are carotenoid derivatives having exceptional hydrophilicity and oral absorptivity. A carotenoid-related compound represented by the formula (in the formula, X represents a carbonyl group or a methylene group, and Z1 and Z2 are ...  
WO/2020/021021A1
The present invention relates to ortho substituted phenoxypropylamino and benzyloxypropylamino derivatives having pharmacological activity towards the α2δ subunit of the voltage-gated calcium channel, in particular to ortho substituted...  
WO/2020/011086A1
Involved are a class of benzodiazepine heterocyclic compounds, a preparation method therefor and the use thereof, as well as a pharmaceutical composition containing the compound. In particular, the present invention relates to the compou...  
WO/2019/246541A1
The application relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers thereof, which modulate the activity of EGFR, a pharmaceutical composition comprising said compounds, and methods of treatin...  
WO/2019/245047A1
The purpose of the present invention is to provide a technique for imaging the brain of a living animal and application of the technique. A radiolabeled dibenzoazepine derivative, which shows excellent brain transferability, high recepto...  
WO/2019/222298A1
The present invention provides methods of use for compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds, including compounds of Formula (I) or prodmgs thereof; for treating diseases and disorders such as cancer.  
WO/2019/168688A9
The present invention includes a solid lyophilized form of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza- benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I) and the process of producing the ...  
WO/2019/215427A1
A process for forming a carbon-carbon bond to couple an aryl or heteroaryl group of a first compound with an alkyl or cycloalkyl moietyof a second compound, the process comprising reacting the first compound with the second compound in t...  
WO/2019/173327A1
Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).  
WO/2019/164947A1
The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method o...  
WO/2019/164948A1
The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, ...  
WO/2019/120212A1
Disclosed in the present invention is a new class of compounds that act as indoleamine-pyrrole 2,3-dioxygenase (IDO) inhibitors, and specifically disclosed thereby are a compound represented by formula (I) and a pharmaceutically acceptab...  
WO/2019/115429A1
The invention relates to compounds according to the general formula (I) or a pharmaceutically acceptable salt of an inorganic or organic acid, a hydrate, a stereoisomer or a solvate thereof, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 a...  
WO/2019/103658A2
The invention relates to novel compounds that are derivatives of 1,4-benzodiazapin-2-one, having the general formula (I) and being limited to structural variants (1-6), on the condition that: а) structures 1 (R1=Br, R4=F), 3 (R1=OCF3, R...  
WO/2019/099560A1
The present subject matter provides compositions, formulations and methods for preventing or reducing proliferation or migration of retinal cells or epithelial to mesenchymal transition in ocular cells or cells from other tissues.  
WO/2019/094903A1
The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors. The present invention also relates to p...  

Matches 1 - 50 out of 2,671